BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Monday reported a loss of $71.3 million in its second quarter.

The Boulder, Colorado-based company said it had a loss of 50 cents per share. Losses, adjusted for non-recurring costs, were 43 cents per share.

The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share.

The biopharmaceutical company posted revenue of $32.1 million in the period, also falling short of Street forecasts. Three analysts surveyed by Zacks expected $37.8 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CLVS at https://www.zacks.com/ap/CLVS

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News